Thursday, March 24, 2016

BRIEF-Portola Pharmaceuticals announces topline results from Phase 3 apex trial of betrixaban

* Announces topline results from phase 3 apex trial of

betrixaban for prevention of blood clots in acute medically ill

patients

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)